SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
NCT07347288
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
PTCL
Interventions
DRUG:
SHR2554 Tablets
Sponsor
The First Affiliated Hospital with Nanjing Medical University